Mitgliederinformationen
Dr Marta Morales Ballús
Spanien
Team
Dr Jaume Català Mora
Spanien
Dr Elisa Carreras
Spanien
Dr Itziar Alonso
Spanien
Dr Isabel Ayet
Spanien
Dr Ester Casas
Spanien
Optometrist Ana Díaz
Spanien
Dr Jesús Díaz
Spanien
Optometrist Enric Puigventos
Spanien
Optometrist Carles Fresno
Spanien
Dr Carmen García Vicuña
Spanien
Dr Hugo Gonzalez
Spanien
Optometrist Enrique Jimenez
Spanien
Dr Ana Llorca
Spanien
Dr Antonio Federico Martinez Monstseny
Spanien
Dr Joan Prat
Spanien
Dr Gemma Romeu
Spanien
Dr Alicia Serra
Spanien
Optometrist Simone Suh
Spanien
Dr Mariona Vidal
Spanien
Optometrist Begoña Yeste
Spanien
Dr Núria Planas
Spanien
HCP-Zentrum
Kontakt
Hospital Sant Joan de Déu, Spain
Klinische Studien
A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).
MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation